Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesLong-Term Debt IssuancesNet Cash FlowNet IncomeShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Inhibrx Biosciences (INBX) Cash from Investing Activities: 2023-2024

Historic Cash from Investing Activities for Inhibrx Biosciences (INBX) over the last 2 years, with Dec 2024 value amounting to -$2.6 million.

  • Inhibrx Biosciences' Cash from Investing Activities rose 97.17% to -$7,000 in Q3 2025 from the same period last year, while for Sep 2025 it was -$291,000, marking a year-over-year increase of 95.17%. This contributed to the annual value of -$2.6 million for FY2024, which is 43.46% up from last year.
  • Latest data reveals that Inhibrx Biosciences reported Cash from Investing Activities of -$2.6 million as of FY2024, which was up 43.46% from -$4.6 million recorded in FY2023.
  • In the past 5 years, Inhibrx Biosciences' Cash from Investing Activities ranged from a high of -$2.6 million in FY2024 and a low of -$4.6 million during FY2023.
  • Moreover, its 2-year median value for Cash from Investing Activities was -$3.6 million (2023), whereas its average is -$3.6 million.
  • Data for Inhibrx Biosciences' Cash from Investing Activities shows a peak YoY spiked of 43.46% (in 2024) over the last 5 years.
  • Over the past 2 years, Inhibrx Biosciences' Cash from Investing Activities (Yearly) stood at -$4.6 million in 2023, then skyrocketed by 43.46% to -$2.6 million in 2024.